Overcoming Clinical Challenges in BRIC Markets - Russia


Applied Clinical Trials

Thomson Reuters Cortellis Competitive Intelligence

Read the first installment of this report on Brazil here.

Figure 3A:
Current clinical trial approval timelines in Russia average three to four months. However, unethical conduct in the country has been revealed in surveys and remarks by sponsors. Biogen Idec provided an example at the global clinical trials conference: in 2013, the company shut down all Russian sites for a Phase II trial—representing one quarter of the study’s patients—because investigators did not want their trial income reported to the state employers. Although it does not appear that global sponsors are largely pulling out of Russia, clinical trial initiation has declined in number since its peak in 2012.

SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.